← All Lexicon Pharmaceuticals, INC filings

Lexicon Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
LXRX
Lexicon Pharmaceuticals, INC
10-K: Lexicon Pharma: 2025 Annual Report Reveals Pipeline Progress
Lexicon Pharmaceuticals' 2025 annual report highlights significant pipeline advancements, including key licensing deals and a reduced net loss, despite ongoing regulatory challenges for ZYNQUISTA.
NASDAQ
LXRX
Lexicon Pharmaceuticals, INC
10-K: Lexicon Pharmaceuticals Reports 2024 Results, Focuses on Key Drug Programs
Lexicon Pharmaceuticals' 2024 10-K filing highlights ongoing drug development, commercialization efforts, and a strategic licensing agreement with Viatris.
NASDAQ
LXRX
Lexicon Pharmaceuticals, INC
10-K: Lexicon Pharmaceuticals Reports Full Year 2023 Results, Highlights Commercial Progress and Pipeline Development
Lexicon Pharmaceuticals' 2023 annual report details the commercial launch of INPEFA for heart failure, progress in sotagliflozin development for type 1 diabetes and hypertrophic cardiomyopathy, and advancement of LX9211 for neuropathic pain.